Tags

Type your tag names separated by a space and hit enter

Smoking and warfarin disposition.
Clin Pharmacol Ther. 1979 Mar; 25(3):309-15.CP

Abstract

Nine cigarette smokers ingested an average daily 0.032 mg/kg dose of sodium warfarin for 2 wk while continuing to smoke and for an additional 2 wk after having abstained from cigarette smoking for a month washout phase. Steady-state plasma levels of warfarin, clearances, t 1/2, apparent volumes of distribution, steady-state prothrombin times, and plasma thiocyanate levels were measured during both the smoking and nonsmoking phases. During the nonsmoking phase there was a 13% increase in average steady-state warfarin level and a 13% decrease in warfarin clearance rate. There also was a 23% increase in warfarin t 1/2 and an 11% increase in the apparent volume of distribution. Prothrombin time did not change. Thiocyanate levels were 3 to 4 times as high during the smoking than the nonsmoking phase. It appears that cigarette smoking does affect warfarin clearance, t 1/2, and apparent volume of distribution, though the net effect on warfarin's pharmacodynamic activity is negligible, at least at doses which are ineffective therapeutically.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

761442

Citation

Bachmann, K, et al. "Smoking and Warfarin Disposition." Clinical Pharmacology and Therapeutics, vol. 25, no. 3, 1979, pp. 309-15.
Bachmann K, Shapiro R, Fulton R, et al. Smoking and warfarin disposition. Clin Pharmacol Ther. 1979;25(3):309-15.
Bachmann, K., Shapiro, R., Fulton, R., Carroll, F. T., & Sullivan, T. J. (1979). Smoking and warfarin disposition. Clinical Pharmacology and Therapeutics, 25(3), 309-15.
Bachmann K, et al. Smoking and Warfarin Disposition. Clin Pharmacol Ther. 1979;25(3):309-15. PubMed PMID: 761442.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Smoking and warfarin disposition. AU - Bachmann,K, AU - Shapiro,R, AU - Fulton,R, AU - Carroll,F T, AU - Sullivan,T J, PY - 1979/3/1/pubmed PY - 1979/3/1/medline PY - 1979/3/1/entrez SP - 309 EP - 15 JF - Clinical pharmacology and therapeutics JO - Clin Pharmacol Ther VL - 25 IS - 3 N2 - Nine cigarette smokers ingested an average daily 0.032 mg/kg dose of sodium warfarin for 2 wk while continuing to smoke and for an additional 2 wk after having abstained from cigarette smoking for a month washout phase. Steady-state plasma levels of warfarin, clearances, t 1/2, apparent volumes of distribution, steady-state prothrombin times, and plasma thiocyanate levels were measured during both the smoking and nonsmoking phases. During the nonsmoking phase there was a 13% increase in average steady-state warfarin level and a 13% decrease in warfarin clearance rate. There also was a 23% increase in warfarin t 1/2 and an 11% increase in the apparent volume of distribution. Prothrombin time did not change. Thiocyanate levels were 3 to 4 times as high during the smoking than the nonsmoking phase. It appears that cigarette smoking does affect warfarin clearance, t 1/2, and apparent volume of distribution, though the net effect on warfarin's pharmacodynamic activity is negligible, at least at doses which are ineffective therapeutically. SN - 0009-9236 UR - https://www.unboundmedicine.com/medline/citation/761442/Smoking_and_warfarin_disposition_ DB - PRIME DP - Unbound Medicine ER -